SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

Clinical trial NCT07182721 · RECRUITING

Trial details

NCT number: NCT07182721
Sponsor: Fudan University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer SKB264 Inetetamab

Start date: 2025-09-30
Primary completion: 2028-09-30
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.